Home › Research › Topics › efficacy
efficacy
805 studies tagged efficacy, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
805 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Cognitive alterations show greatest correlation with total CGIC.
-
Donepezil was relatively well tolerated; adverse events were consistent with current labeling.
-
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial.
-
In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks.
-
Short-term administration of latrepirdine is well tolerated in patients with HD and may have a beneficial effect on cognition.
-
Forty-eight patients were randomized to treatment with either topiramate or risperidone, and 41 patients (21 of 25 in topiramate group and 20 of 23 in risperidone group) completed the trial.
-
Among caregivers, this small randomized controlled trial found that escitalopram use resulted in improvement in depression, resilience, burden and distress, and quality of life.
-
Sertraline did not demonstrate efficacy for the treatment depression symptoms in patients with AD.
-
Accumulating evidence indicates that p38 mitogen-activated protein kinase (MAPK) could play more than one role in Alzheimer's disease (AD) pathophysiology and that patients suffering from AD dementia could benefit from p38 MAPK inhibitors.
-
Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD.
-
74/100
No significant differences were found in the primary efficacy analysis.
-
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus.
-
Donepezil and memantine have similar modest clinical and spectroscopic effect on mild to moderate AD.
-
There are no empiric data to support guidelines for duration of therapy with antidementia drugs.
-
Treatment success in Alzheimer disease (AD) trials is generally based on benefits over placebo-treated controls.
-
Addition of ATX to ongoing cholinesterase-inhibitor therapy was generally well tolerated but did not significantly improve cognitive function.
-
65/100
Overall, 318 patients with AD completed BPST with an improvement of 5.6 points on the total Cohen-Mansfield Agitation Inventory (CMAI; mean [SD], 63.3 [16.0] to 57.7 [18.4], t = 4.8, df = 317, p 95% of patients.
-
The findings from this survey indicate that cholinesterase inhibitors and/or NMDA receptor antagonists are prescribed for a subset of patients with advanced dementia and that a proportion of hospice medical directors report clinical benefit from the ongoing use of these agents.
-
61/100
The single nucleotide polymorphism rs1080985 in the CYP2D6 gene may influence the clinical efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD).
-
Earlier NH admission of Australian compared to U.K. and U.S. subjects may be due to differences in health care, NH systems, availability, and affordability.
-
Coptidis Rhizoma and its isolated alkaloids are reported to possess a variety of activities, including neuroprotective and antioxidant effects.
-
Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects.
-
Alzheimer's disease (AD) is an age-related dementia, characterized by amyloid plaques, neurofibrillary tangles, neuroinflammation, and neuronal loss in the brain.
-
Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragraph delayed recall score, showed that higher BDI scores were associated with progression to AD (p = 0.03).
-
The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer's disease (AD), the Alphase study.
-
Recent studies have also shown that cannabinoids may have more specific effects in interrupting the pathological process in Alzheimer's disease.
-
Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD.
-
The MAPT Study is the first preventive trial involving multidomain interventions.
-
48/100
Infectious agents have been proposed as potential causes of Alzheimer's disease (AD).
-
This study failed to find a beneficial effect of exogenous melatonin, consistent with a number of other studies.
-
The dual primary efficacy endpoint was not reached.
-
This double-blind randomized controlled trial of vitamin therapy demonstrates a strong correlation between serum tHcy and plasma Abeta40 concentrations in subjects with ischemic stroke.
-
The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer's disease (AD) (including mixed-type dementia) or dementia with Lewy bodies.
-
Effective counseling and support interventions can reduce symptoms of depression in caregivers when patients are taking donepezil.
-
In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI.
-
69/100
Despite evidence of target engagement as indicated by an increase in serum insulin-like growth factor-1, the human growth hormone secretagogue MK-677 25 mg was ineffective at slowing the rate of progression of Alzheimer disease.
-
The use of positive modulators of PLA2 (especially of cPLA2 and iPLA2) or supplementation with dietary lipid compounds (e.g., arachidonic acid) in combination with cognitive training could be a valuable therapeutic strategy for cognitive enhancement in early-stage AD.
-
Trial registration clinicaltrials.gov Identifier: NCT00056225.
-
OSA may aggravate cognitive dysfunction in dementia and thus may be a reversible cause of cognitive loss in patients with AD.
-
The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown.
-
Ginseng is one of the most popular herbs worldwide.
-
Group differences were seen in skin and subcutaneous tissue concerns (P=.05), including 3 possible drug rashes and 3 reports of hair color change in the treatment groups.
-
Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication ability with the social environment and the ability to carry out daily activities.
-
In nursing home residents with AD and psychosis, aripiprazole did not confer specific benefits for the treatment of psychotic symptoms; but psychological and behavioral symptoms, including agitation, anxiety, and depression, were improved with aripiprazole, with a low risk of AEs.
-
20 participants--15 in the AN1792 group, five in the placebo group--died before follow-up started.
-
The low likelihood of patients with cAF in general practice remaining on treatment long-term indicates that not all benefits as observed in clinical trials may be achieved in usual clinical practice.
-
Our results suggest that when using semantic encoding, older normal subjects may be aided by anticholinesterase treatment.
-
Apathy is a common behavioral symptom of Alzheimer's disease (AD), being present in up to 70% of patients.
From across this tag
8 of the 796 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial
- TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets
- Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
- ActiTect: a generalizable machine learning pipeline for REM sleep behavior disorder screening through standardized actigraphy
- Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
- Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review
- Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials
- FDA Grants Accelerated Approval for ADUHELM (aducanumab) as the First and Only Alzheimer's Disease Treatment to Address a Defining Pathology of the Disease